Metabolic adaptive responses in cancer. Project Summary Oncogenic mutations alter signaling pathways to drive metabolic pathways that meet the bioenergetic and biosynthetic demands of increased tumor cell growth and resistance to cell death. The ribosomal protein S6 kinase 1 (S6K1) supports glycolysis downstream of oncogenic mutations to support growth and survival. Increased glycolysis renders cells """"""""addicted"""""""" to glucose metabolism, and cells are consequently hypersensitive to interruptions in glycolytic metabolism. We recently investigated S6K1 as a target for reducing cellular glycolysis in leukemia cells. Decreased glycolysis upon S6K1 inactivation triggered cell death only cells that were transformed by loss of Pten. Other leukemia cells expressing the BCR-ABL oncogene adapted to decreased glycolysis in the absence of S6K1 signaling, initiating a Metabolic Adaptive Response, or MAR, to mediate cancer cell survival despite S6K1 inactivation. We show here that BCR-ABL cells activate fatty acid oxidation (FAO) in response to loss of S6K1. Treatment of cells with a FAO inhibitor enhanced the cytotoxic responses of BCR-ABL+ cells to S6K1 inactivation or mTORC1 inactivation. Thus, by understanding and targeting the MAR in leukemia cells, we were able to dramatically enhance the potential therapeutic efficacy of inhibitors targeting S6K1 and mTORC1. Experiments in this application are focused on determining the molecular mechanisms and functional impact of the S6K1-regulated MAR. Using metabolomics, we will delineate the precise FAO metabolic pathways that respond to S6K1 activity. In addition, we will test specific signaling mediators downstream of S6K1 BCR-ABL for their role in mediating the MAR. Autophagic metabolism is a MAR program that, along with FAO, is known to prevent cytotoxic responses to mTORC1 inhibitors. We will test here whether targeting S6K1 circumvents autophagic metabolism compared to targeting mTORC1. Finally, we will develop in vivo models of leukemia that will allow us to specifically test the contributions of S6K1-glycolysis and the FAO-MAR on leukemogenesis and therapeutic response. The project combines mechanistic analysis of metabolism and signal transduction with translational analysis of functional impact, and will yield the experimental framework for developing therapies that target S6K1 and the FAO Metabolic Adaptive Response in cancer cells.
Metabolic adaptive responses in cancer. Project Narrative/Relevance It is well known that cancer cells develop resistance to chemotherapeutic drugs by acquiring mutations in oncogenes and tumor suppressor genes. An important but understudied mechanism in chemotherapy resistance is the ability of tumor cells to use metabolic adaptation to enhance cancer cell survival. In this research proposal, we will identify and target the metabolic pathways that cancer cells use to resist chemotherapeutics, to enhance the efficacy of existing drugs and begin to develop new drugs for next- generation cancer therapy.
| Liu, Hongqi; Feng, Xizhi; Ennis, Kelli N et al. (2017) Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia. Cell Rep 18:2088-2095 |
| Ghosh, Joydeep; Kobayashi, Michihiro; Ramdas, Baskar et al. (2016) S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance. J Clin Invest 126:2621-5 |
| Vallabhapurapu, Subrahmanya D; Noothi, Sunil K; Pullum, Derek A et al. (2015) Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nat Commun 6:8428 |
| Shin, Sejeong; Buel, Gwen R; Wolgamott, Laura et al. (2015) ERK2 Mediates Metabolic Stress Response to Regulate Cell Fate. Mol Cell 59:382-98 |
| Hall, Daniel P; Cost, Nicholas G; Hegde, Shailaja et al. (2014) TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell 26:738-53 |
